BioNTech SE (BVMF:B1NT34)
Brazil · Delayed Price · Currency is BRL 32.33
-1.92 (-5.61%)
At close: Apr 28, 2026
BioNTech SE Employees
BioNTech SE had 7,807 employees as of December 31, 2025. The number of employees increased by 1,035 or 15.28% compared to the previous year.
Employees
7,807
Change (1Y)
1,035
Growth (1Y)
15.28%
Revenue / Employee
2.38M BRL
Profits / Employee
-941.11K BRL
Market Cap
128.51B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 7,807 | 1,035 | 15.28% |
| Dec 31, 2024 | 6,772 | 639 | 10.42% |
| Dec 31, 2023 | 6,133 | 1,603 | 35.39% |
| Dec 31, 2022 | 4,530 | 1,448 | 46.98% |
| Dec 31, 2021 | 3,082 | 1,141 | 58.78% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Raia Drogasil | 73,895 |
| Empreendimentos Pague Menos | 28,207 |
| Fleury | 28,000 |
| Diagnósticos da América | 26,255 |
| Dimed S.A. Distribuidora de Medicamentos | 11,282 |
| Hypera | 10,564 |
| Blau Farmacêutica | 1,900 |
BioNTech SE News
- 8 days ago - Two experimental drugs showed striking early results against pancreatic cancer - WSJ
- 9 days ago - BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026 - GlobeNewsWire
- 19 days ago - BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer - GlobeNewsWire
- 4 weeks ago - Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles - Reuters
- 5 weeks ago - BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer - GlobeNewsWire
- 7 weeks ago - BioNTech Stock Tanks As Outlook, Founder Exit Rattle Bulls - Benzinga
- 7 weeks ago - BioNTech SE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 7 weeks ago - One simple reason why BioNTech stock is a raging buy on today's crash - Invezz